BRPI0815957A2 - "composto, composição farmacêutica, métodos e respectivo uso de 1,2,3-triazin-4-onas trissubstituídas e 1,3-pirimidinonas trissubstituídas para a melhora das respostas sinápticas glutamatérgicas" - Google Patents

"composto, composição farmacêutica, métodos e respectivo uso de 1,2,3-triazin-4-onas trissubstituídas e 1,3-pirimidinonas trissubstituídas para a melhora das respostas sinápticas glutamatérgicas"

Info

Publication number: BRPI0815957A2
Authority: BR; Brazil
Prior art keywords: trisubstituted; pyrimidinones; triazin; ones; improvement
Prior art date: 2007-09-20

Application number

BRPI0815957A

Other languages

English (en)

Inventor

Alisala Kashinatham

J Street Leslie

Mueller Rudolf

Rachwal Stanislaw

Original Assignee

Cortex Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-20

Filing date

2008-09-19

Publication date

2019-09-24

2008-09-19 Application filed by Cortex Pharma Inc filed Critical Cortex Pharma Inc

2019-09-24 Publication of BRPI0815957A2 publication Critical patent/BRPI0815957A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Anesthesiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BRPI0815957A 2007-09-20 2008-09-19 "composto, composição farmacêutica, métodos e respectivo uso de 1,2,3-triazin-4-onas trissubstituídas e 1,3-pirimidinonas trissubstituídas para a melhora das respostas sinápticas glutamatérgicas" BRPI0815957A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US99454807P	2007-09-20	2007-09-20
PCT/US2008/010877 WO2009038752A2 (en)	2007-09-20	2008-09-19	3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses

Publications (1)

Publication Number	Publication Date
BRPI0815957A2 true BRPI0815957A2 (pt)	2019-09-24

Family

ID=40468690

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0815957A BRPI0815957A2 (pt)	2007-09-20	2008-09-19	"composto, composição farmacêutica, métodos e respectivo uso de 1,2,3-triazin-4-onas trissubstituídas e 1,3-pirimidinonas trissubstituídas para a melhora das respostas sinápticas glutamatérgicas"

Country Status (13)

Country	Link
US (1)	US20100267728A1 (pt)
EP (1)	EP2195303A4 (pt)
JP (1)	JP2010540436A (pt)
KR (1)	KR20100063087A (pt)
CN (1)	CN101801939A (pt)
AU (1)	AU2008301884B2 (pt)
BR (1)	BRPI0815957A2 (pt)
CA (1)	CA2700158A1 (pt)
EA (1)	EA201000516A1 (pt)
MX (1)	MX2010002890A (pt)
NZ (1)	NZ584098A (pt)
WO (1)	WO2009038752A2 (pt)
ZA (1)	ZA201002016B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA200904826B (en)	2007-01-03	2010-09-29	Cortex Pharma Inc	3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
CA2674321A1 (en) *	2007-01-03	2008-07-17	Cortex Pharmaceuticals, Inc.	3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
JP5694765B2 (ja)	2007-05-17	2015-04-01	コーテックスファーマシューティカルズ，インコーポレイテッド	グルタミン酸作動性シナプス反応を増強するための二置換アミド
US8168632B2 (en)	2007-08-10	2012-05-01	Cortex Pharmaceuticals, Inc.	Bicyclic amide derivatives for the treatment of respiratory disorders
ES2560095T3 (es)	2007-08-10	2016-02-17	Cortex Pharmaceuticals, Inc.	Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas
US20110257186A1 (en) *	2010-04-15	2011-10-20	Staubli Ursula V	Compositions and methods for treating visual disorders
FR3019464B1 (fr) *	2014-04-07	2016-05-06	Servier Lab	Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
CN106226509B (zh) *	2016-08-12	2019-09-06	中国人民解放军第四军医大学	一种在小鼠前扣带回皮层诱发dse现象的方法
GB201702221D0 (en)	2017-02-10	2017-03-29	Univ Of Sussex	Compounds
CN108084104A (zh) *	2017-12-27	2018-05-29	温州大学	1，2，3-苯并三嗪-4（3h）-酮化合物的合成方法
GB201803340D0 (en)	2018-03-01	2018-04-18	Univ Of Sussex	Compounds
CN116005178B (zh) *	2023-01-28	2023-07-18	淮北师范大学	一种1,2-二氢喹唑啉类化合物的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5776935A (en) *	1996-07-25	1998-07-07	Merz & Co. Gmbh & Co.	Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission
DE19900544A1 (de) *	1999-01-11	2000-07-13	Basf Ag	Verwendung von Verbindungen der Formel I zur Prophylaxe und Therapie der zerebralen Ischämie
US7612060B2 (en) *	2004-10-13	2009-11-03	Amgen Inc.	Triazoles and methods of use
CA2674321A1 (en) *	2007-01-03	2008-07-17	Cortex Pharmaceuticals, Inc.	3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses

2008
- 2008-09-19 NZ NZ584098A patent/NZ584098A/en not_active IP Right Cessation
- 2008-09-19 JP JP2010525829A patent/JP2010540436A/ja active Pending
- 2008-09-19 CN CN200880107960A patent/CN101801939A/zh active Pending
- 2008-09-19 EP EP08831417A patent/EP2195303A4/en not_active Withdrawn
- 2008-09-19 AU AU2008301884A patent/AU2008301884B2/en not_active Expired - Fee Related
- 2008-09-19 CA CA2700158A patent/CA2700158A1/en not_active Abandoned
- 2008-09-19 US US12/733,822 patent/US20100267728A1/en not_active Abandoned
- 2008-09-19 EA EA201000516A patent/EA201000516A1/ru unknown
- 2008-09-19 WO PCT/US2008/010877 patent/WO2009038752A2/en not_active Ceased
- 2008-09-19 KR KR1020107006440A patent/KR20100063087A/ko not_active Withdrawn
- 2008-09-19 MX MX2010002890A patent/MX2010002890A/es active IP Right Grant
- 2008-09-19 BR BRPI0815957A patent/BRPI0815957A2/pt not_active IP Right Cessation
2010
- 2010-03-19 ZA ZA2010/02016A patent/ZA201002016B/en unknown

Also Published As

Publication number	Publication date
US20100267728A1 (en)	2010-10-21
CA2700158A1 (en)	2009-03-26
EA201000516A1 (ru)	2010-10-29
AU2008301884A1 (en)	2009-03-26
ZA201002016B (en)	2010-12-29
KR20100063087A (ko)	2010-06-10
EP2195303A4 (en)	2011-07-20
CN101801939A (zh)	2010-08-11
WO2009038752A2 (en)	2009-03-26
NZ584098A (en)	2012-05-25
AU2008301884B2 (en)	2012-12-20
EP2195303A2 (en)	2010-06-16
MX2010002890A (es)	2010-07-02
WO2009038752A3 (en)	2009-07-09
JP2010540436A (ja)	2010-12-24

Similar Documents

Publication	Publication Date	Title
BRPI0818459A2 (pt)	2015-04-14	Composição farmacêutica adequada para uso oftálmico.
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0819755A2 (pt)	2018-07-17	composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI1013763A2 (pt)	2015-08-25	Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto
PT2170959E (pt)	2014-01-07	Anticorpos para o receptor humano de morte programada pd-1
CL2008000947A1 (es)	2008-10-10	Uso de un antagonista de la proteina beta-klotho (klb) para tratar trastornos asociados a la expresion o actividad de klb.
BRPI0811805A2 (pt)	2014-11-11	"artigo absorvente alongado e método para sua fabricação".
BRPI0822033A2 (pt)	2015-07-21	Composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, kit
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0808813A2 (pt)	2016-08-02	método para a preparação de compostos de borracha, e, uso de compostos
BRPI0811262A2 (pt)	2014-11-04	Composto, composto ou sal do mesmo, composição farmacêutica, modulador de receptor de glicocorticóide, método para prevenção e/ou tratamento de bistúrbios metabólicos, doenças inflamatórias, doenças auto-imunes, doenças alérgicas, doenças do sistema nervoso central, doenças cardiovasculares, doenças relacionadas com homeostase ou glaucoma, e uso de pelo menos um composto ou um sal do mesmo
BRPI0914371A2 (pt)	2019-09-24	"composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação"
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0819501A2 (pt)	2015-05-26	"dispositivo para fototerapia, método cosmético para bronzeamento, uso do dispositivo, kit, uso de curcumia, curcuminoides, pró-drogas ou metabólitos dos mesmos e composição farmacêutica"
BRPI0821915A2 (pt)	2015-06-16	Piridil-n-(1,3,4)-tiadiazol-2-il-benzeno sulfonamidas cíclicas, processos para sua preparação e seu uso como produtos farmacêuticos
IT1399590B1 (it)	2013-04-26	Apparato e kit per incapsulare almeno un composto ad uso terapeutico e/o diagnostico all'interno di eritrociti
BRPI0813587A2 (pt)	2014-12-30	Composto, uso do mesmo, e, composição farmacêutica
AP2502A (en)	2012-10-23	3-substituted-[1,2,3]-benzotriazinone compound forenhancing glutamatergic synaptic responses
BRPI0903914A2 (pt)	2015-07-21	Uso de um composto, método para analisar a eficácia de uma composição de liberação prolongada, e, composição farmacêutica.
BRPI0716250A2 (pt)	2013-10-08	Composto ou sal ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças, e, uso de um composto
BRPI0817883A2 (pt)	2014-10-07	Produto aprimorado de uso tópico para alivio de dores
BRPI0806529A2 (pt)	2014-04-22	Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta
BRPI0820388A2 (pt)	2014-10-14	Molécula concatenada para a modulação da atividade do sistema imunológico humano e animal, composição, kit, fármaco e uso

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application fees: application dismissed [chapter 8.6 patent gazette]
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.